Red Yeast Rice (Monacolin K).

Monacolin K inhibits HMG-CoA reductase, the same enzyme that feeds the mevalonate branch making the isoprenoid tail of ubiquinone, so endogenous CoQ10 output falls as cholesterol synthesis falls. Co-supplementing CoQ10 replaces what that shared upstream step no longer supplies to muscle and heart mitochondria.

Monacolin K slows hepatic cholesterol production while berberine raises LDL-receptor density and lowers PCSK9, increasing clearance from the blood. Production and clearance are separate levers, which is why this pairing has been a fixture of lipid-support formulas for two decades.

Bergamot's HMG-flavanones engage the same hepatic cholesterol-synthesis enzyme monacolin K acts on, and the extract also carries citrus polyphenols that support normal antioxidant status. The pair spreads the same lipid support across two sources rather than raising monacolin alone.

Monacolin K inhibits HMG-CoA reductase, which sits upstream of both cholesterol and the farnesyl units used for the ubiquinone tail. Ubiquinol is the reduced circulating form, so supplying it covers the branch the inhibition also slows.

Niacin acts on hepatic VLDL secretion and adipose lipolysis rather than on cholesterol synthesis, so the levers differ. The additive risk of muscle complaints when a monacolin and high-dose niacin are combined is equally well described and needs care.

Sterols compete with cholesterol inside intestinal micelles and reduce absorption, while monacolin K reduces hepatic synthesis. Addressing both sides of cholesterol balance is standard formulation practice.

Oat beta-glucan raises intestinal viscosity and increases faecal bile acid loss, so the liver spends cholesterol replacing them. That is independent of the HMG-CoA reductase step.

Psyllium gel binds bile acids and carries them out, driving hepatic conversion of cholesterol into new bile acids. The mechanism complements rather than duplicates monacolin K.

EPA and DHA lower hepatic VLDL triglyceride assembly and raise fatty acid oxidation, a different arm of lipid metabolism. Combining them addresses triglycerides and cholesterol in one formula.

Guggulsterones antagonise the farnesoid X receptor and shift bile acid and lipid gene expression. The transcriptional lever is distinct from direct enzyme inhibition.

Monacolin K is processed in the liver as a CYP3A4 substrate, and silymarin mildly inhibits CYP3A4 and some transporters. Co-dosing therefore raises monacolin exposure above what the label dose suggests.

Hyperforin induces CYP3A4 and P-glycoprotein through PXR, and monacolin K is a CYP3A4 substrate. Co-dosing clears the monacolin faster, so the formula delivers less than its label suggests.

A randomised trial of a supplement built on monacolins together with gamma-oryzanol and gamma-aminobutyric acid reported lipid marker changes in adults with mildly raised blood lipids. Gamma-oryzanol is a rice bran sterol ferulate that acts on cholesterol absorption rather than synthesis. The pair is the tested combination, not two separately validated ingredients.

Gamma-aminobutyric acid was the third component of the monacolin and gamma-oryzanol formulation tested by De Lellis and colleagues. Its contribution within that blend cannot be separated from the other two components. Cite the combination, not GABA on its own.

Natto-derived and monacolin-containing preparations are combined commercially and have been examined together in the recent cardiovascular literature. The routes are unrelated, one on fibrin handling and one on HMG-CoA reductase. The evidence is discussed at review level rather than as an isolated combination trial.

Pectin binds bile acids in the intestinal lumen and increases their faecal excretion, which pulls hepatic cholesterol into replacement bile acid synthesis. Monacolin K acts at the synthesis enzyme instead. Two different points in one loop is the ordinary basis for pairing a soluble fibre with a monacolin ingredient.

Glucomannan forms a highly viscous gel that slows micelle formation and reduces ileal bile acid reabsorption. That is a lumen-level action, independent of the hepatic enzyme monacolin K inhibits. The viscosity also slows absorption of anything taken at the same time, which is a timing consideration rather than a benefit.

Artichoke leaf increases bile production and its cynarin fraction is described as affecting hepatic cholesterol handling. That sits downstream of the mevalonate step monacolin K blocks. The pairing is formulation convention and has not been trialled as a pair.

S-allylcysteine from aged garlic is described as modulating hepatic lipid handling by a route separate from HMG-CoA reductase inhibition. Cardiovascular blends carry both regularly. No combination measurement exists for the pair.

Catechins reduce micellar solubilisation of cholesterol in the gut, limiting absorption of what arrives in the lumen. Monacolin K limits what the liver makes. Both carry their own hepatic monitoring considerations, which a formulator combining them should state.

Tocotrienols reduce HMG-CoA reductase activity by accelerating degradation of the enzyme, while monacolin K binds its active site competitively. Two mechanisms on one enzyme can add or interfere and the human result has not been settled. Read this as mechanistic rather than clinical.

Quercetin inhibits CYP3A4 in laboratory systems, and the lactone form of monacolin K is cleared by CYP3A4. Slowing that clearance would raise systemic exposure. This is a pairing to check with a clinician rather than an additive benefit.

Resveratrol inhibits several cytochrome P450 enzymes including CYP3A4 in vitro, the route that clears monacolin K. The magnitude in a person is unknown. Flag it by direction rather than assuming either an additive or a cancelling effect.

Nutraceutical combinations that modulate lipid and glucose handling together have been described in adults at cardiometabolic risk, and chromium is a common component of them on insulin signalling grounds. Chromium's own effect size across trials is inconsistent. The pairing sits at Early for that reason.

Cinnamon polyphenols are described as supporting normal post-meal glucose handling, a different axis from cholesterol synthesis but one often addressed in the same product. Cassia cinnamon also carries coumarin, which matters for daily intake in a product taken continuously. That is a composition point, not a benefit.

Gymnemic acids reduce sweet taste perception and are studied for intestinal glucose uptake. They appear alongside monacolins in blends aimed at normal lipid and glucose handling together. Nothing measures the two as a pair.

Alpha-linolenic acid affects hepatic triglyceride handling, a lipid fraction monacolins move less than LDL cholesterol. Products covering the full panel often carry both. The combination itself is untested.

MK-7 carboxylates matrix Gla protein, the protein that governs where calcium is deposited in soft tissue. That is adjacent to, not part of, the cholesterol synthesis pathway. Blends combine them on mechanistic grounds only.

Alpha-lipoic acid recycles glutathione and other redox partners and takes part in mitochondrial dehydrogenase complexes. It appears in cardiometabolic blends alongside monacolin ingredients. The rationale is general redox chemistry rather than anything specific to monacolin K.